Intraoperative Ultrasonography-Guided Positioning of Iodine 125 Plaque Brachytherapy in the Treatment of Choroidal Melanoma

Chang, Melinda Y.; Kamrava, Mitchell; Demanes, D. Jeffrey; Leu, Min Y.; Agazaryan, Nzhde; Lamb, James; Moral, Joel N.; Almanzor, Robert; McCannel, Tara A.

doi:10.1016/j.ophtha.2011.11.011

Cited by 73 publications

(25 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The use of US positioning confirmation is strongly suggested, especially for posterior lesions, as recent experiences show a relative local failure rate of 0% when it is performed [33]. During surgical procedures, the plaque needs to be manipulated by following specific rules.…”

Section: Step 4 Surgery: Plaque Implantationmentioning

confidence: 99%

INTERACTS (INTErventional Radiotherapy ACtive Teaching School) guidelines for quality assurance in choroidal melanoma interventional radiotherapy (brachytherapy) procedures

Tagliaferri¹,

Pagliara²,

Boldrini³

et al. 2017

jcb

View full text Add to dashboard Cite

Eye plaque brachytherapy represents a safe and effective therapeutic approach for choroidal melanoma, combining clinical outcomes with an eye and visual preservation.As it represents a complex procedure, a specific quality assurance program is strongly suggested to improve patients and operators safety, and to reduce possible complications linked to surgical procedure and radiation exposure.The aim of this paper is to describe the INTERACTS (Interventional Radiotherapy Active Teaching School) guidelines for quality assurance in choroidal melanoma interventional radiotherapy (brachytherapy) used in our institution.

show abstract

Section: Step 4 Surgery: Plaque Implantationmentioning

confidence: 99%

INTERACTS (INTErventional Radiotherapy ACtive Teaching School) guidelines for quality assurance in choroidal melanoma interventional radiotherapy (brachytherapy) procedures

Tagliaferri¹,

Pagliara²,

Boldrini³

et al. 2017

jcb

View full text Add to dashboard Cite

show abstract

“…Prior studies suggest that following brachytherapy there is often greater than 90% local tumor control for choroidal melanomas [1,7,8,9], with recurrence rates ranging from 0 to 18% [3,7]. The COMS reported a 10.3% rate of local tumor recurrence at 5 years following 125 I brachytherapy [1].…”

Section: Discussionmentioning

confidence: 99%

“…A series by the University of Southern California, using 3D imaging for plaque planning, achieved a local tumor control rate of 97% at 5 years [8]. Another study used intraoperative ultrasound guidance for brachytherapy, and found a statistically lower rate of 2-year local treatment failure than the COMS trial [9]. In a study by Char et al [5], the annual incidence of recurrent melanoma after 125 I brachytherapy was 2.8% between 0 and 5 years, and 1.9% between 5 and 15 years.…”

Section: Discussionmentioning

confidence: 99%

Late Apical Recurrence of Choroidal Melanoma 10 Years after Successful Treatment with Brachytherapy

Shih

Corrêa

et al. 2017

Ocul Oncol Pathol

View full text Add to dashboard Cite

Purpose: To describe late apical relapse of a choroidal melanoma at the site of fine needle aspiration biopsy 10 years following successful treatment with ¹²⁵I brachytherapy. Methods: Retrospective case report of a 78-year-old male presenting 10 years following successful ¹²⁵I brachytherapy for a choroidal melanoma with a medium-sized nodular amelanotic tumor recurrence at the site of the prior tumor biopsy. Results: Fundus photography and B-scan ultrasound documented the findings at presentation at our institution. The patient was followed closely for 8 weeks while information was retrieved from the treating institution. During this short period, there was significant apical tumor growth. Additionally, there was a clear clinical change compared to the last documented photos from 5 years prior at the treating institution. Enucleation was recommended. Pathological analysis confirmed the diagnosis of recurrent choroidal melanoma at the apex of the treated lesion, at the site of prior biopsy. Systemic surveillance was negative for metastatic disease. Conclusion: Current literature suggests the majority of choroidal melanoma recurrences occur within 5 years following treatment. However, this case of recurrence 10 years after brachytherapy emphasizes the importance of life-long ophthalmic care for these patients. Additionally, this case demonstrates the possibility of a rare recurrence at a prior biopsy site.

show abstract

“…If the rectus muscles or their insertions prevented implantation of the plaque, they were disinserted and reattached at the time of plaque removal. The location of the plaque with respect to the tumor was confirmed and optimized with intraoperative ultrasonography [19]. Fine needle aspiration biopsy of the tumor was performed for cytology and molecular prognostic studies.…”

Section: Methodsmentioning

confidence: 99%

Outcomes of Glaucoma Drainage Device Surgery in Eyes with Treated Uveal Melanoma

Fatehi¹,

McCannel²,

Giaconi³

et al. 2018

Ocul Oncol Pathol

View full text Add to dashboard Cite

Aim: We report patient safety and intraocular pressure (IOP) control after placement of a glaucoma drainage device (GDD) in eyes with a history of treated malignant uveal melanoma. Methods: A retrospective review of the records of patients with uveal melanoma was performed. Outcomes were local tumor recurrence, rate of metastases, and tonometric success, based on survival curves, defined as IOP < 21 mm Hg. Results: Eleven eyes with choroidal melanoma, 4 with iris melanoma, and 1 with ciliary body melanoma were followed for a median (interquartile range) of 2.1 (1.1–3.2) years. Two subjects developed liver metastases; one had monosomy 3 and tumor gene expression profile class 2. The other case with ciliary body melanoma was negative for monosomy 3. There were no cases of local treatment failure. Mean preoperative IOP decreased from 30.5 ± 7.7 to 15.9 ± 8.1 mm Hg at 1 year after surgery (1-year success rate 80%). Conclusions: Our case series with a median follow-up of 2 years shows that placing a GDD in patients with treated uveal melanoma does not expose patients to greater risk of local or extraocular recurrence. A larger series and longer follow-up time are required to fully evaluate the safety of GDDs in this clinical scenario.

show abstract

Intraoperative Ultrasonography-Guided Positioning of Iodine 125 Plaque Brachytherapy in the Treatment of Choroidal Melanoma

Cited by 73 publications

References 20 publications

INTERACTS (INTErventional Radiotherapy ACtive Teaching School) guidelines for quality assurance in choroidal melanoma interventional radiotherapy (brachytherapy) procedures

INTERACTS (INTErventional Radiotherapy ACtive Teaching School) guidelines for quality assurance in choroidal melanoma interventional radiotherapy (brachytherapy) procedures

Late Apical Recurrence of Choroidal Melanoma 10 Years after Successful Treatment with Brachytherapy

Outcomes of Glaucoma Drainage Device Surgery in Eyes with Treated Uveal Melanoma

Contact Info

Product

Resources

About